Shu-Nan Qi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2836464/publications.pdf Version: 2024-02-01



Shul-Nan Oi

#	Article	IF	CITATIONS
1	Preoperative versus postoperative chemo-radiotherapy for locally advanced gastric cancer: a multicenter propensity score-matched analysis. BMC Cancer, 2022, 22, 212.	2.6	5
2	First-Line Chemoradiation With or Without Chidamide (Tucidinostat) in Patients With Intermediate- and High-Risk Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma: A Randomized Phase 2 Study in China. International Journal of Radiation Oncology Biology Physics, 2022, 113, 833-844.	0.8	6
3	Progressionâ€free survival at 3 years is a reliable surrogate for 5â€year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma. Cancer Medicine, 2022, , .	2.8	6
4	Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making. Leukemia, 2021, 35, 130-142.	7.2	70
5	Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Leukemia, 2021, 35, 1671-1682.	7.2	14
6	Safety and efficacy of preoperative chemoradiotherapy in fit older patients with intermediate or locally advanced rectal cancer evaluated by comprehensive geriatric assessment: A planned interim analysis of a multicenter, phase II trial. Journal of Geriatric Oncology, 2021, 12, 572-577.	1.0	6
7	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1064-1081.	0.8	26
8	Radiomics Analysis of Fat-Saturated T2-Weighted MRI Sequences for the Prediction of Prognosis in Soft Tissue Sarcoma of the Extremities and Trunk Treated With Neoadjuvant Radiotherapy. Frontiers in Oncology, 2021, 11, 710649.	2.8	8
9	Quality of Life After Partial or Whole-Breast Irradiation in Breast-Conserving Therapy for Low-Risk Breast Cancer: 1-Year Results of a Phase 2 Randomized Controlled Trial. Frontiers in Oncology, 2021, 11, 738318.	2.8	2
10	Down-staging depth score could be a survival predictor for locally advanced gastric cancer patients after preoperative chemoradiotherapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 447-456.	2.2	1
11	POstmastectomy radioThErapy in Node-posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a study protocol for a multicenter prospective phase III randomized controlled trial. BMC Cancer, 2021, 21, 1185.	2.6	7
12	Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer. JAMA Network Open, 2021, 4, e2136116.	5.9	2
13	Development and Validation of an MRI-Based Nomogram Model for Predicting Disease-Free Survival in Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy. Frontiers in Oncology, 2021, 11, 784156.	2.8	0
14	Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review. Leukemia, 2020, 34, 2576-2591.	7.2	18
15	Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions. BMC Cancer, 2020, 20, 1155.	2.6	6
16	First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG. Blood Advances, 2020, 4, 3141-3153.	5.2	35
17	Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China. Journal of Clinical Oncology, 2020, 38, 3604-3614.	1.6	58
18	Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis. Frontiers in Oncology, 2020, 10, 571390.	2.8	2

Shu-Nan Qi

#	Article	IF	CITATIONS
19	Locoregional recurrence patterns in women with breast cancer who have not undergone post-mastectomy radiotherapy. Radiation Oncology, 2020, 15, 212.	2.7	4
20	Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma. Annals of Hematology, 2020, 99, 1303-1309.	1.8	1
21	Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy. Frontiers in Oncology, 2020, 10, 605750.	2.8	7
22	Prognosis and Prophylactic Regional Nodal Irradiation in Breast Cancer Patients With the First Isolated Chest Wall Recurrence After Mastectomy. Frontiers in Oncology, 2020, 10, 600525.	2.8	4
23	Riskâ€based, responseâ€adapted therapy for earlyâ€stage extranodal nasalâ€type <scp>NK</scp> /Tâ€cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study. American Journal of Hematology, 2020, 95, 1047-1056.	4.1	25
24	Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine,) Tj ETQq0 (0 ng₿T /O	venlæck 10 Tf
25	Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 352-360.	10.7	258
26	The Optimal Use of Imaging in Radiation Therapy for Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group (ILROG). International Journal of Radiation Oncology Biology Physics, 2019, 104, 501-512.	0.8	30
27	Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leukemia and Lymphoma, 2019, 60, 2669-2678.	1.3	20
28	Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma. JAMA Network Open, 2019, 2, e190194.	5.9	23
29	LncRNA and mRNA signatures associated with neoadjuvant chemoradiotherapy downstaging effects in rectal cancer. Journal of Cellular Biochemistry, 2019, 120, 5207-5217.	2.6	18
30	Effect of age as a continuous variable on survival outcomes and treatment selection in patients with extranodal nasal-type NK/T-cell lymphoma from the China Lymphoma Collaborative Group (CLCG). Aging, 2019, 11, 8463-8473.	3.1	11
31	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2018, 100, 652-669.	0.8	71
32	Riskâ€dependent curability of radiotherapy for elderly patients with earlyâ€stage extranodal nasalâ€type NK/Tâ€cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Cancer Medicine, 2018, 7, 5952-5961.	2.8	14
33	Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Advances, 2018, 2, 2369-2377.	5.2	24
34	Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG). Radiotherapy and Oncology, 2018, 129, 3-9.	0.6	30
35	Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study. International Journal of Radiation Oncology Biology Physics, 2018, 102, 61-70.	0.8	15
36	Can fit elderly patients evaluated by comprehensive geriatric assessment with intermediate or locally advanced rectal cancer receive preoperative chemoradiotherapy? An interim analysis of a multicenter phase II trial Journal of Clinical Oncology, 2018, 36, e15688-e15688.	1.6	1

Shu-Nan Qi

#	Article	IF	CITATIONS
37	Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma. JAMA Oncology, 2017, 3, 83.	7.1	64
38	Patterns of Primary Tumor Invasion and Regional Lymph Node Spread Based on Magnetic Resonance Imaging in Early-Stage Nasal NK/T-cell Lymphoma: Implications for Clinical Target Volume Definition and Prognostic Significance. International Journal of Radiation Oncology Biology Physics, 2017, 97, 50-59.	0.8	19
39	Phase II clinical trial of first-line combination of radiation followed by gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy for early-stage extranodal natural killer/T-cell lymphoma with unfavorable prognostic factors: The GREEN study (NCT02276248) Journal of Clinical Oncology, 2017, 35. 7540-7540.	1.6	0
40	Dosimetric and Clinical Outcomes With Intensity Modulated Radiation Therapy After Chemotherapy for Patients With Early-Stage Diffuse Large B-cell Lymphoma of Waldeyer Ring. International Journal of Radiation Oncology Biology Physics, 2016, 96, 379-386.	0.8	6
41	Radiotherapy Alone With Curative Intent in Patients With Stage I Extranodal Nasal-Type NK/T-Cell Lymphoma. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1809-1815.	0.8	75
42	Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma. Clinical Cancer Research, 2009, 15, 2905-2912.	7.0	105
43	Diffuse large Bâ€cell lymphoma. Cancer, 2009, 115, 4980-4989.	4.1	23
44	Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood, 2009, 114, 4771-4776	1.4	83